Tevogen Bio Holdings Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
TVGN Nasdaq 2830 tevogen.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Tevogen Bio Holdings Inc.

CD8 Technology Signs Letter of Intent for Tevogen Bio’s In-House Manufacturing Facility, Marking First Phase of Up to $50 Million Commitment - Apr 30th, 2025 7:49 pm
Tevogen sees launch year oncology business revenue $1B - Apr 29th, 2025 8:50 pm
Tevogen Informs Public Shareholders About DRS Accounts And Differences to Brokerage Accounts - Apr 29th, 2025 5:48 pm
Tevogen CEO to Join Dialogue on Paths to Liquidity: Strategies for Adapting to a Volatile Market at BioNJ’s Fifteenth Annual Bio Partnering Conference with Experts from J.P. Morgan, RSM, and Cantor Fitzgerald - Apr 29th, 2025 12:00 pm
Tevogen Reaffirms Oncology Top-Line Revenue Forecast of $1 Billion in Launch Year and Cumulative 5-Year Estimate Between $10 Billion and $14 Billion - Apr 28th, 2025 8:36 pm
Tevogen Bio Announces 2025 Annual Meeting - Apr 25th, 2025 6:33 pm
Tevogen Bio Finalizes Agreement for Company’s Own Cell Therapy Production Facility - Apr 17th, 2025 6:54 pm
Tevogen Bio Commissions Databricks to Accelerate Development of PredicTcell, a Precision AI Tool for Target Prediction - Apr 15th, 2025 6:03 pm
Tevogen Announces Tevogen Generics, a New Effort in Support of President Trump’s Initiative to Encourage Pharmaceutical Manufacturing in United States - Apr 9th, 2025 6:45 pm
Tevogen Bio CIO and Head of Tevogen.AI Presented at AI x Bio Philly Event Showcasing Philly’s Leading AI Biotechs - Apr 8th, 2025 9:53 pm
Tevogen Bio Highlights Most Recent Insider Ownership of 74%; Management Maintains Conviction in the Company’s Mission - Apr 7th, 2025 7:58 pm
Tevogen Bio CEO Named to NJBIZ 2025 Health Care Power List as Company Advances Commercialization; Reaffirms Timeframe on Previously Announced Forecast - Mar 26th, 2025 7:12 pm
Tevogen Bio Appoints David E. Banko as Global Head of Government Affairs and Patient Access, Advances Commercialization Plan - Mar 25th, 2025 5:11 pm
Tevogen Bio Announces Unique T Cell Vaccine Under Development and Files Patent with the USPTO - Mar 10th, 2025 4:40 pm
Tevogen Bio’s CIO & Head of Tevogen.AI, Mittul Mehta, Featured Speaker at Proskauer’s AI Discussion Panel - Mar 7th, 2025 9:09 pm
Tevogen Bio to Receive $8 Million of Non-Dilutive Grant Funding, Reiterates Efficient Operations - Mar 3rd, 2025 5:52 pm
Tevogen Bio Founder and CEO Dr. Ryan Saadi Named to 2025 NJBIZ Power 100, Celebrating Innovation and Leadership in Accessible T Cell Therapy - Feb 28th, 2025 6:17 pm
Tevogen Bio’s First Trading Year Efficiency: 600% Higher Market Cap Per Team Member, 79% Insider-Owned - Feb 21st, 2025 8:28 pm
Tevogen Bio Shares 2024 Financing Activity on One Year Anniversary of Becoming a Publicly Listed Company; Highlights Operational Efficiency - Feb 14th, 2025 6:16 pm
Tevogen Bio CEO Addresses Short Selling and Its Potential Impact on the Nation’s Health and Prosperity - Feb 14th, 2025 4:52 pm